S&P 500   3,933.92
DOW   33,597.92
QQQ   280.53
How To Be Persuasive With Your Body Language
Tiny $4 Company to “Steal” Billions From Tesla?  (Ad)
How to Play Apple and Amazon Heading in 2023
Low Beta, High Yield Campbell Soup Company Is Mmm Mmm Good
Market Wizard who made $95 million for his clients in 2008 – and predicted the 2022 collapse (Ad)
Ulta Issues A Beautiful FY Outlook, But Is the Stock A Buy Now?
Microsoft strikes 10-year deal with Nintendo on Call of Duty
Why Your IRA Could Crash on January 16th? (Ad)
Could trawler cams help save world's dwindling fish stocks?
Southwest Airlines brings back dividend as travel rebounds
S&P 500   3,933.92
DOW   33,597.92
QQQ   280.53
How To Be Persuasive With Your Body Language
Tiny $4 Company to “Steal” Billions From Tesla?  (Ad)
How to Play Apple and Amazon Heading in 2023
Low Beta, High Yield Campbell Soup Company Is Mmm Mmm Good
Market Wizard who made $95 million for his clients in 2008 – and predicted the 2022 collapse (Ad)
Ulta Issues A Beautiful FY Outlook, But Is the Stock A Buy Now?
Microsoft strikes 10-year deal with Nintendo on Call of Duty
Why Your IRA Could Crash on January 16th? (Ad)
Could trawler cams help save world's dwindling fish stocks?
Southwest Airlines brings back dividend as travel rebounds
S&P 500   3,933.92
DOW   33,597.92
QQQ   280.53
How To Be Persuasive With Your Body Language
Tiny $4 Company to “Steal” Billions From Tesla?  (Ad)
How to Play Apple and Amazon Heading in 2023
Low Beta, High Yield Campbell Soup Company Is Mmm Mmm Good
Market Wizard who made $95 million for his clients in 2008 – and predicted the 2022 collapse (Ad)
Ulta Issues A Beautiful FY Outlook, But Is the Stock A Buy Now?
Microsoft strikes 10-year deal with Nintendo on Call of Duty
Why Your IRA Could Crash on January 16th? (Ad)
Could trawler cams help save world's dwindling fish stocks?
Southwest Airlines brings back dividend as travel rebounds
S&P 500   3,933.92
DOW   33,597.92
QQQ   280.53
How To Be Persuasive With Your Body Language
Tiny $4 Company to “Steal” Billions From Tesla?  (Ad)
How to Play Apple and Amazon Heading in 2023
Low Beta, High Yield Campbell Soup Company Is Mmm Mmm Good
Market Wizard who made $95 million for his clients in 2008 – and predicted the 2022 collapse (Ad)
Ulta Issues A Beautiful FY Outlook, But Is the Stock A Buy Now?
Microsoft strikes 10-year deal with Nintendo on Call of Duty
Why Your IRA Could Crash on January 16th? (Ad)
Could trawler cams help save world's dwindling fish stocks?
Southwest Airlines brings back dividend as travel rebounds
NASDAQ:GRPH

Graphite Bio - GRPH Stock Forecast, Price & News

$3.43
-0.07 (-2.00%)
(As of 12/7/2022 12:00 AM ET)
Add
Compare
Today's Range
$3.35
$3.58
50-Day Range
$3.06
$3.61
52-Week Range
$2.07
$13.39
Volume
43,814 shs
Average Volume
369,294 shs
Market Capitalization
$199.46 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$12.83

Graphite Bio MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
274.1% Upside
$12.83 Price Target
Short Interest
Healthy
4.71% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.00mentions of Graphite Bio in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($1.85) to ($2.36) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.92 out of 5 stars

Medical Sector

691st out of 1,027 stocks

Biological Products, Except Diagnostic Industry

107th out of 171 stocks

GRPH stock logo

About Graphite Bio (NASDAQ:GRPH) Stock

Graphite Bio, Inc., a clinical-stage gene editing company, engages in developing therapies for serious and life-threatening diseases in the United States. It offers GPH101, a gene-edited autologous hematopoietic stem cell product candidate to directly correct the mutation that causes sickle cell disease and restore normal adult hemoglobin expression; GPH201 for the treatment of X-linked severe combined immunodeficiency syndrome; and GPH301, a product candidate for the treatment of Gaucher disease, a genetic disorder that results in a deficiency in the glucocerebrosidase enzyme. The company was formerly known as Integral Medicines, Inc., and changed its name to Graphite Bio, Inc. in August 2020. Graphite Bio, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.

Receive GRPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Graphite Bio and its competitors with MarketBeat's FREE daily newsletter.

GRPH Stock News Headlines

GRPH Graphite Bio, Inc.
Graphite Bio Inc.
Where Graphite Bio Stands With Analysts
Graphite Bio: Selling For Much Less Than Net Cash
Analyst Ratings for Graphite Bio
What 4 Analyst Ratings Have To Say About Graphite Bio
See More Headlines
Receive GRPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Graphite Bio and its competitors with MarketBeat's FREE daily newsletter.

GRPH Company Calendar

Last Earnings
11/09/2022
Today
12/07/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
3/20/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:GRPH
Fax
N/A
Employees
69
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$12.83
High Stock Price Forecast
$18.00
Low Stock Price Forecast
$6.00
Forecasted Upside/Downside
+274.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
6 Analysts

Profitability

Net Income
$-70,760,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$6.61 per share

Miscellaneous

Free Float
35,793,000
Market Cap
$199.46 million
Optionable
Not Optionable
Beta
0.44

Key Executives

  • Dr. Joshua Lehrer-Graiwer FACC (Age 48)
    M.D., Pres, CEO & Director
    Comp: $724.58k
  • Dr. Matthew Porteus M.D. (Age 57)
    Ph.D., Academic Founder & Director
    Comp: $90.77k
  • Dr. Maria Grazia Roncarolo M.D. (Age 68)
    Ph.D., Academic Founder & Chair of Scientific Advisory Board
    Comp: $70k
  • Mr. Philip P. Gutry (Age 49)
    Chief Bus. Officer
    Comp: $541.33k
  • Dr. Daniel Dever Ph.D.
    Co-Founder & Head of Discovery Research
  • Ms. Alethia Rene Young (Age 43)
    Chief Financial Officer
  • Dr. Christine Garrett P.M.P. (Age 51)
    Ph.D., Chief of Staff & Sr. VP of Operations
  • Mr. Jerry Cacia (Age 55)
    Chief Technical Officer
  • Dr. Jane Grogan Ph.D. (Age 54)
    Chief Scientific Officer
  • Stephanie Yao
    VP of Communications & Investor Relations













GRPH Stock - Frequently Asked Questions

Should I buy or sell Graphite Bio stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Graphite Bio in the last twelve months. There are currently 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" GRPH shares.
View GRPH analyst ratings
or view top-rated stocks.

What is Graphite Bio's stock price forecast for 2023?

6 Wall Street analysts have issued 12-month price objectives for Graphite Bio's shares. Their GRPH share price forecasts range from $6.00 to $18.00. On average, they anticipate the company's share price to reach $12.83 in the next twelve months. This suggests a possible upside of 274.1% from the stock's current price.
View analysts price targets for GRPH
or view top-rated stocks among Wall Street analysts.

How have GRPH shares performed in 2022?

Graphite Bio's stock was trading at $12.43 at the beginning of the year. Since then, GRPH shares have decreased by 72.4% and is now trading at $3.43.
View the best growth stocks for 2022 here
.

When is Graphite Bio's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, March 20th 2023.
View our GRPH earnings forecast
.

How were Graphite Bio's earnings last quarter?

Graphite Bio, Inc. (NASDAQ:GRPH) issued its quarterly earnings results on Wednesday, November, 9th. The company reported ($0.45) earnings per share for the quarter, topping the consensus estimate of ($0.49) by $0.04.

When did Graphite Bio IPO?

(GRPH) raised $224 million in an initial public offering on Friday, June 25th 2021. The company issued 14,000,000 shares at $15.00-$17.00 per share.

What is Graphite Bio's stock symbol?

Graphite Bio trades on the NASDAQ under the ticker symbol "GRPH."

Who are Graphite Bio's major shareholders?

Graphite Bio's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include EcoR1 Capital LLC (2.72%), Vanguard Group Inc. (2.06%), Privium Fund Management UK Ltd (0.97%), Renaissance Technologies LLC (0.90%), BlackRock Inc. (0.83%) and Prosight Management LP (0.61%). Insiders that own company stock include Biocapital LP Samsara and Phil Gutry.
View institutional ownership trends
.

How do I buy shares of Graphite Bio?

Shares of GRPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Graphite Bio's stock price today?

One share of GRPH stock can currently be purchased for approximately $3.43.

How much money does Graphite Bio make?

Graphite Bio (NASDAQ:GRPH) has a market capitalization of $199.46 million. The company earns $-70,760,000.00 in net income (profit) each year or ($1.76) on an earnings per share basis.

How can I contact Graphite Bio?

The official website for the company is www.graphitebio.com. The company can be reached via phone at 650-484-0886 or via email at ir@graphitebio.com.

This page (NASDAQ:GRPH) was last updated on 12/8/2022 by MarketBeat.com Staff